Shire Pharmaceuticals Group Plc
Zug, Switzerland (ots/PRNewswire) - This Press Release is intended for Global Use If approved, Natpar would be the first licensed recombinant parathyroid hormone in Europe for the management of chronic hypoparathyroidism, the only endocrine-deficiency disorder with no hormone treatment[1] Shire plc (LSE: SHP, ...
Québec, Canada/Lausanne, Switzerland (ots) - GenePOC announces the commercialization of its Clostridium difficile and Group B Strep molecular tests in Europe, along with onboarding additional partners to cover the EMEA market GenePOC, Inc. (GenePOC) a member of the Debiopharm Group is proud to announce that it has started the commercialization of its first two CE-IVD marked tests, GenePOC(TM) CDiff and GenePOC(TM) GBS ...
Shire Pharmaceuticals Group Plc
Zug, Switzerland (ots/PRNewswire) - Shire presentations at EAHAD 2017 underscore the company's leadership in improving global standards of care Shire plc (LSE: SHP, NASDAQ: SHPG), the leading biotechnology company focused on serving individuals with rare diseases, presented its new estimate of the Global Annual Bleed Rate (GABR), an effort to build on current global ...
International Union Against Cancer (UICC)
Davos, Switzerland (ots/PRNewswire) - - New city-level initiative launched in partnership between the Union for International Cancer Control (UICC), the World Economic Forum and World Bank - A commitment to saving lives by helping country and city leaders improve the health of their citizens and reduce inequities in access to quality cancer treatment and care - A ...
Rheinfelden, Switzerland (ots/PRNewswire) - Zeria Pharmaceutical Co., Ltd launched Zentacort® 3mg capsules (generic name: Budesonide) in Japan on November 29, 2016. Zentacort® is sold as Entocort(TM) in more than 40 countries and recommended as first line therapy for treatment in Crohn's Disease (CD) in various ...
Zug, Switzerland (ots/PRNewswire) - Pala Investments ("Pala"), an investment company focused on the mining and metals value chain, announces today the successful completion of the sale of its 53 percent interest in Sierra Rutile Limited ("Sierra Rutile"), the world's largest producer of natural rutile, to Iluka Resources. The transaction valued Sierra Rutile at £215 ...
Lugano, Switzerland and San Diego (ots/PRNewswire) - Phase 2 study results presented at American Society of Hematology Annual Meeting on Saturday, December 3, 2016 Global Phase 3 study site recruitment is ongoing Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, ...
Rheinfelden, Switzerland (ots/PRNewswire) - Tillotts Pharma AG (Switzerland) introduced a new advanced enteric coating for solid dosage forms at this year's annual meeting of the American Association of Pharmaceutical Scientists. The OPTICORE(TM) coating technology comprises two trigger systems and an accelerator to ...
Lugano, Switzerland and San Diego (ots/PRNewswire) - Data to be presented on December 3, 2016; Abstract now available online Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel ...
Lugano, Switzerland (ots/PRNewswire) - ~ Helsinn Group creates new investment fund in 40th anniversary year ~ ~ The new fund will focus on supporting early-stage investment opportunities in areas of high unmet patient need ~ Helsinn, the Swiss Pharmaceutical Group focused on building quality cancer care, today introduces Helsinn Investment Fund S.A. ("the Fund"), a fund focused on early-stage investment opportunities in ...
Rheinfelden, Switzerland (ots/PRNewswire) - Zeria Pharmaceutical Co., Ltd. has received the approval for a new drug application for Zentacort 3mg capsules from the Ministry of Health, Labour and Welfare (MHLW) in Japan for the indication of the improvement of Crohn's Disease (CD). Following the acquisition of the ...
Shire Pharmaceuticals Group Plc
Zug, Switzerland (ots/PRNewswire) - The positive opinion is based on a pivotal Phase 3 study showing that ONIVYDE combined with chemotherapy significantly increased overall survival (OS) in patients with metastatic pancreatic cancer after previous gemcitabine based therapy Shire plc (LSE: SHP, NASDAQ: SHPG) today ...
Shire Pharmaceuticals Group Plc
Zug, Switzerland (ots/PRNewswire) - HyQvia (Human Normal Immunoglobulin 10% and Recombinant Human Hyaluronidase) is the only subcutaneous IG treatment for primary and certain secondary immunodeficiencies that can be administered in one site, once a month (up to every four weeks) Shire plc (LSE: SHP, NASDAQ: SHPG) is launching a pediatric indication for HyQvia (Human ...
Shire Pharmaceuticals Group Plc
Zug, Switzerland (ots/PRNewswire) - This press release is intended for a global audience. First therapy indicated in the EU for use in patients aged one year and above with SBS, a rare gastrointestinal condition Shire (LSE: SHP, NASDAQ: SHPG) today announced that the European Commission has granted extension of ...
Montreux, Switzerland (ots/PRNewswire) - On the occasion of the 50th edition of the Montreux Jazz Festival, Domaine Clarence Dillon and Clarence Dillon Wines have signed a partnership agreement for the next three years by which Clarendelle is proud to become an exclusive foreign wines partner of the Montreux Jazz ...
Shire Pharmaceuticals Group Plc
Zug, Switzerland (ots/PRNewswire) - - Cuvitru (IG 20mg/ml solution for subcutaneous injection) builds on company's broad portfolio of IG treatments gained through combination with Baxalta - New option to treat primary and certain secondary immunodeficiencies can help meet patient needs related to number of infusion ...
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm today announced the start of a phase II clinical trial for Debio 1143 in combination with standard of care Carboplatin and Paclitaxel in Epithelial Ovarian Cancer Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global ...
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), a Swiss-based company, part of Debiopharm Group(TM), today announced that the FDA Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation to Debio 1143 for treatment of ovarian cancer. Orphan Drug Designation ...
Shire Pharmaceuticals Group Plc
Zug, Switzerland (ots/PRNewswire) - Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the extension of the approval of Revestive[®*] (teduglutide) 5 mg powder and solvent for ...
JTI Japan Tobacco International AG
Geneva, Switzerland (ots/PRNewswire) - The Directive's Aim is to Harmonize Regulations - Not Disrupt the Free Movement of Goods Across the EU Just two weeks before the Tobacco Products Directive (TPD2) comes into force in the 28 EU Member States, the Court of Justice of the European Union (CJEU) has rejected tobacco manufacturers' claims against TPD2. (Logo: ...
Zürich, Switzerland (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Today, on World Haemophilia Day, Novo Nordisk announces that the grant scheme to support and encourage research projects focused on the psychosocial issues faced by people with haemophilia is open for ...
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), a Swiss-based company, part of Debiopharm Group(TM), today announces that non-clinical data on the clinical-stage investigational compound Debio 1347/CH5183284 (FGFR 1,2,3 inhibitor) will be presented at the 2016 Annual Meeting of the ...
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm will be present at ECCMID in Amsterdam to share new data supporting the clinical development of its first in class Staphylococcus-selective antibiotic Debio 1450 Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced three communications ...
Tolochenaz, Switzerland (ots/PRNewswire) - European innovation delivers titanium family of cages to support twin surgical objectives of bone fusion and sagittal realignment for improved patients' outcomes. Medtronic PLC (NYSE: MDT), the global leader in medical technology, today announced the launch of AVILA(TM), its new family of interbody fusion devices for L2-S1 levels in open and minimally invasive ALIF and OLIF ...
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company today announces that the Tokyo District Court granted Debiopharm an overall victory for the first instance demanding the suspension of patent infringement of ...
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced a collaboration in order to supply triptorelin pamoate 3.75 mg 1-month formulation for patients suffering from salivary gland cancer ...
Lugano, Switzerland (ots/PRNewswire) - ~ 40 years helping patients achieve a better quality of life ~ Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, is delighted to launch its 40th anniversary celebrations in San Francisco, US, at the time of the JP Morgan 34th Annual Healthcare Conference. Helsinn believes its core values of respect, integrity and quality have underpinned four decades of ...
Lausanne, Switzerland and Atlanta (ots/PRNewswire) - Arbor Pharmaceuticals to commercialize triptorelin in sustained-release formulation for the orphan indication central precocious puberty Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, and ...
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced that the European Medicines Agency (EMA) granted Orphan Drug Designation to Debio 1143 for treatment of Ovarian Cancer affecting around 154 ...
Mandaluyong, Philippines and Lausanne, Switzerland (ots/PRNewswire) - Pamorelin® one-, three- and six-month dosing option now available to patients in the Philippines United Laboratories Inc. (Unilab) and Debiopharm International SA (Debiopharm) announce the signature of an exclusive agreement for the distribution ...